Item Type | Name |
Concept
|
Acute Disease
|
Concept
|
Brain Injuries
|
Concept
|
Colitis
|
Concept
|
Hematoma
|
Concept
|
Depressive Disorder, Major
|
Concept
|
Cerebral Hemorrhage
|
Concept
|
Hypertension
|
Concept
|
Chronic Disease
|
Concept
|
Glioma
|
Concept
|
Otorhinolaryngologic Diseases
|
Concept
|
Migraine Disorders
|
Concept
|
Hemangioma, Cavernous
|
Concept
|
Skin Diseases
|
Concept
|
Central Nervous System Neoplasms
|
Concept
|
Recovery of Function
|
Concept
|
Genetic Association Studies
|
Concept
|
Chronic Pain
|
Concept
|
Hemangioma, Cavernous, Central Nervous System
|
Concept
|
Intracranial Hemorrhages
|
Concept
|
Stroke
|
Concept
|
Neurodegenerative Diseases
|
Concept
|
Brain Neoplasms
|
Concept
|
Brain Ischemia
|
Concept
|
Disease Models, Animal
|
Concept
|
Hemorrhage
|
Concept
|
Neoplasms
|
Concept
|
Seizures
|
Academic Article
|
Quantitative Susceptibility Mapping in Cerebral Cavernous Malformations: Clinical Correlations.
|
Academic Article
|
Surgical Performance in Minimally Invasive Surgery Plus Recombinant Tissue Plasminogen Activator for Intracerebral Hemorrhage Evacuation Phase III Clinical Trial.
|
Academic Article
|
Quantitative susceptibility mapping as a monitoring biomarker in cerebral cavernous malformations with recent hemorrhage.
|
Academic Article
|
Cerebral cavernous malformations form an anticoagulant vascular domain in humans and mice.
|
Academic Article
|
Trial Readiness in Cavernous Angiomas With Symptomatic Hemorrhage (CASH).
|
Academic Article
|
Symptomatic Hemorrhagic Complications in Clot Lysis: Evaluation of Accelerated Resolution of Intraventricular Hemorrhage Phase III Clinical Trial (CLEAR III): A Posthoc Root-Cause Analysis.
|
Academic Article
|
Plasma Biomarkers of Inflammation Reflect Seizures and Hemorrhagic Activity of Cerebral Cavernous Malformations.
|
Academic Article
|
Atorvastatin Treatment of Cavernous Angiomas with Symptomatic Hemorrhage Exploratory Proof of Concept (AT CASH EPOC) Trial.
|
Academic Article
|
Plasma Biomarkers of Inflammation and Angiogenesis Predict Cerebral Cavernous Malformation Symptomatic Hemorrhage or Lesional Growth.
|
Academic Article
|
Rho Kinase Inhibition Blunts Lesion Development and Hemorrhage in Murine Models of Aggressive Pdcd10/Ccm3 Disease.
|
Academic Article
|
Surgical Performance Determines Functional Outcome Benefit in the Minimally Invasive Surgery Plus Recombinant Tissue Plasminogen Activator for Intracerebral Hemorrhage Evacuation (MISTIE) Procedure.
|
Academic Article
|
Biomarkers of cavernous angioma with symptomatic hemorrhage.
|
Academic Article
|
Symptomatic Brain Hemorrhages from Cavernous Angioma After Botulinum Toxin Injections, a Role of TLR/MEKK3 Mechanism? Case Report and Review of the Literature.
|
Academic Article
|
Subclinical imaging changes in cerebral cavernous angiomas during prospective surveillance.
|
Academic Article
|
Antibodies in cerebral cavernous malformations react with cytoskeleton autoantigens in the lesional milieu.
|
Academic Article
|
Novel Murine Models of Cerebral Cavernous Malformations.
|
Academic Article
|
A Roadmap for Developing Plasma Diagnostic and Prognostic Biomarkers of Cerebral Cavernous Angioma With Symptomatic Hemorrhage (CASH).
|
Academic Article
|
Intracerebral Hemorrhage Volume Reduction and Timing of Intervention Versus Functional Benefit and Survival in the MISTIE III and STICH Trials.
|
Academic Article
|
Perfusion and permeability as diagnostic biomarkers of cavernous angioma with symptomatic hemorrhage.
|
Academic Article
|
COVID-19 in a Hemorrhagic Neurovascular Disease, Cerebral Cavernous Malformation.
|
Academic Article
|
Perfusion and Permeability MRI Predicts Future Cavernous Angioma Hemorrhage and Growth.
|
Academic Article
|
Cerebral Hemorrhage: Pathophysiology, Treatment, and Future Directions.
|
Concept
|
Cerebral Intraventricular Hemorrhage
|
Academic Article
|
Impact of socioeconomics and race on clinical follow-up and trial enrollment and adherence in cerebral cavernous malformation.
|
Academic Article
|
Cavernous Angioma Symptomatic Hemorrhage (CASH) Trial Readiness II: Imaging Biomarkers and Trial Modeling.
|
Academic Article
|
Corrigendum to "Antibodies in cerebral cavernous malformations react with cytoskeleton autoantigens in the lesional milieu" [J. Autoimmun. 113 (2020) 102469].
|
Academic Article
|
Trial Readiness of Cavernous Malformations With Symptomatic Hemorrhage, Part II: Biomarkers and Trial Modeling.
|
Academic Article
|
Trial Readiness of Cavernous Malformations With Symptomatic Hemorrhage, Part I: Event Rates and Clinical Outcome.
|
Academic Article
|
Pathologic Features of Brain Hemorrhage After Radiation Treatment: Case Series with Somatic Mutation Analysis.
|